Patents by Inventor Allen A. Thomas
Allen A. Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10889589Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.Type: GrantFiled: May 17, 2019Date of Patent: January 12, 2021Assignee: Array BioPharma Inc.Inventors: Shelley Allen, Steven Wade Andrews, James F. Blake, Barbara J. Brandhuber, Julia Haas, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Allen A. Thomas, Shannon L. Winski
-
Publication number: 20190270749Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.Type: ApplicationFiled: May 17, 2019Publication date: September 5, 2019Applicant: Array BioPharma Inc.Inventors: Shelley Allen, Steven Wade Andrews, James F. Blake, Barbara J. Brandhuber, Julia Haas, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Allen A. Thomas, Shannon L. Winski
-
Patent number: 10351575Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.Type: GrantFiled: November 13, 2013Date of Patent: July 16, 2019Assignee: Array BioPharma Inc.Inventors: Shelley Allen, Steven Wade Andrews, James F. Blake, Barbara J. Brandhuber, Julia Haas, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Allen A. Thomas, Shannon L. Winski
-
Patent number: 10154995Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: August 23, 2017Date of Patent: December 18, 2018Assignees: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
-
Patent number: 9969694Abstract: Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.Type: GrantFiled: November 12, 2013Date of Patent: May 15, 2018Assignee: Array BioPharma Inc.Inventors: James F. Blake, Barbara J. Brandhuber, Julia Haas, Brad Newhouse, Allen A. Thomas, Shannon L. Winski
-
Publication number: 20170348310Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: ApplicationFiled: August 23, 2017Publication date: December 7, 2017Applicants: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
-
Patent number: 9763942Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: June 29, 2016Date of Patent: September 19, 2017Assignees: Genentech, Inc., Array BioPharma Inc.Inventors: James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
-
Publication number: 20160355521Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.Type: ApplicationFiled: November 13, 2013Publication date: December 8, 2016Applicant: Array BioPharma Inc.Inventors: Shelley Allen, Steven Wade Andrews, James F. Blake, Barbara J. Brandhuber, Julia Haas, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Allen A. Thomas, Shannon L. Winski
-
Publication number: 20160303126Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: ApplicationFiled: June 29, 2016Publication date: October 20, 2016Applicants: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
-
Publication number: 20160272592Abstract: Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.Type: ApplicationFiled: November 12, 2013Publication date: September 22, 2016Applicant: ARRAY BIOPHARMA INC.Inventors: James F. Blake, Barbara J. Brandhuber, Julia Haas, Brad Newhouse, Allen A. Thomas, Shannon L. Winski
-
Patent number: 9133187Abstract: Compounds having the formula I wherein Z, Z1 Z2 Z3, R3a, R3b and Rb and as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.Type: GrantFiled: February 28, 2012Date of Patent: September 15, 2015Assignees: ARRAY BIOPHARMA INC., GENENTECH, INC.Inventors: James F. Blake, Huifen Chen, Mark Joseph Chicarelli, Jason Demeese, Rustam Garrey, John J. Gaudino, Robert J. Kaus, Gabrielle R. Kolakowski, Allison L. Marlow, Peter J. Mohr, Li Ren, Jacob Schwarz, Christopher S. Siedem, Allen A. Thomas, Eli Wallace, Steven Mark Wenglowsky, Steven Boyd
-
Publication number: 20130338140Abstract: Compounds having the formula I wherein Z, Z1 Z2 Z, R3a, R3b and Rb and as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.Type: ApplicationFiled: February 28, 2012Publication date: December 19, 2013Applicants: Genetech, Inc., Array BioPharma Inc.Inventors: James F. Blake, Huifen Chen, Mark Joseph Chcarelli, Jason Demeese, Rustam Garrey, John J. Gaudino, Robert J. Kaus, Gabrielle R. Kolakowski, Allison L. Marlow, Peter J. Mohr, Li Ren, Jacob Schwartz, Christopher S. Siedem, Allen A. Thomas, Eli Wallace, Steven Mark Wenglowsky
-
Publication number: 20120157448Abstract: The invention provides novel tricyclic compounds of Formula I? that inhibit ?-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.Type: ApplicationFiled: November 22, 2011Publication date: June 21, 2012Inventors: Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Nicholas C. Kallan, Andrew T. Metcalf, Brad Newhouse, Tony P. Tang, Allen A. Thomas, Michael Siu, Malcolm Huestis, Matthew Volgraf
-
Publication number: 20120083501Abstract: The invention provides novel tricyclic compounds of Formula I? that inhibit ?-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Inventors: Kevin W. Hunt, Tony P. Tang, Allen A. Thomas
-
Publication number: 20120065195Abstract: The invention provides novel spirotetrahydronaphthalene compounds of Formula ? that inhibit ?-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.Type: ApplicationFiled: March 31, 2011Publication date: March 15, 2012Inventors: Christopher T. Clark, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Nicholas C. Kallan, Michael Siu, Allen A. Thomas, Matthew Volgraf
-
Patent number: 8003662Abstract: Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: January 30, 2007Date of Patent: August 23, 2011Assignee: Array BioPharma, Inc.Inventors: James F. Blake, Steven Boyd, Jason De Meese, John J. Gaudino, Allison L. Marlow, Jeongbeob Seo, Allen A. Thomas, Hongqi Tian
-
Publication number: 20100256356Abstract: Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: ApplicationFiled: January 26, 2010Publication date: October 7, 2010Applicants: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Steven Armen Boyd, Jason De Meese, Kin Chiu Fong, John J. Gaudino, Tomas Kaplan, Allison L. Marlow, Jeongbeob Seo, Allen A. Thomas, Hongqi Tian, Frederick Cohen, Wendy B. Young
-
Patent number: 7723330Abstract: Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: March 6, 2007Date of Patent: May 25, 2010Assignees: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Steven Armen Boyd, Jason De Meese, Kin Chiu Fong, John J. Gaudino, Tomas Kaplan, Allison L. Marlow, Jeongbeob Seo, Allen A. Thomas, Hongqi Tian, Frederick Cohen, Wendy B. Young
-
Publication number: 20030078339Abstract: Degradable cross-linkers which are used to form polymer networks which degrade under aqueous conditions are described. These cross-linkers comprise a central polyacid, monomeric or oligomeric degradable regions and an optional water soluble regions. These monomers are preferably polymerized using free radical or condensation polymerization. Degradation occurs at the ester linkages after cross-linking polymer filaments, and results in soluble polymer filaments which may be cleared from the body. Preferred applications of these materials include, for example, controlled release of drugs and cosmetics, tissue engineering, wound healing, hazardous waste remediation, metal chelation, swellable devices for absorbing liquids and the prevention of surgical adhesions.Type: ApplicationFiled: August 27, 2002Publication date: April 24, 2003Inventors: Patrick F. Kiser, Allen A. Thomas
-
Patent number: 6521431Abstract: Biodegradable cross-linkers are provided having a polyacid core with at least two acidic groups covalently connected to reactive groups usable to cross-link polymer filaments. Between at least one reactive group and an acidic group of the polyacid is a biodegradable region which preferably consists of a hydroxyalkyl acid ester sequence having 1, 2, 3, 4, 5 or 6 hydroxyalkyl acid ester groups. The polyacid may be attached to a water soluble region that is attached to the biodegradable region having attached reactive groups. The hydroxyalkyl acid ester group is preferably a lactate or glycolate. Polyacids include diacids, triacids, tetraacids and pentaacids, and the reactive group may contain a carbon-carbon double bond. A network of cross-linked polymer filaments having adefined biodegradation rate can be formed using the cross-linkers. The network may contain biologically active molecules, and can be in the form of a microparticle or nanoparticle, or hydrogel.Type: GrantFiled: June 22, 1999Date of Patent: February 18, 2003Assignee: Access Pharmaceuticals, Inc.Inventors: Patrick F. Kiser, Allen A. Thomas